LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

LLY

729.83

-1.21%↓

JNJ

175.39

-0.94%↓

ABBV

206.2

-1.33%↓

UNH

301.19

-0.76%↓

AZN

79.85

-0.15%↓

Search

Ocular Therapeutix Inc

Отворен

СекторЗдравеопазване

12.44 1.3

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

12.16

Максимум

12.57

Ключови измерители

By Trading Economics

Приходи

-3.8M

-68M

Продажби

2.8M

13M

Марж на печалбата

-503.856

Служители

274

EBITDA

146K

-64M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+36.61% upside

Дивиденти

By Dow Jones

Следващи печалби

13.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

98M

2.1B

Предишно отваряне

11.14

Предишно затваряне

12.44

Настроения в новините

By Acuity

97%

3%

363 / 372 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

Ocular Therapeutix Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.08.2025 г., 22:51 ч. UTC

Печалби

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27.08.2025 г., 23:57 ч. UTC

Печалби

Trip.com Group 1H Rev $4.01B

27.08.2025 г., 23:57 ч. UTC

Печалби

Trip.com Group 1H Adj EPS $1.84

27.08.2025 г., 23:57 ч. UTC

Печалби

Trip.com Group 1H EPS $1.82

27.08.2025 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27.08.2025 г., 23:39 ч. UTC

Печалби

Correction to Nvidia Earnings Article -- WSJ

27.08.2025 г., 22:59 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

27.08.2025 г., 22:59 ч. UTC

Пазарно говорене

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27.08.2025 г., 22:58 ч. UTC

Печалби

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27.08.2025 г., 22:57 ч. UTC

Печалби

South32 FY Free Cash Flow $192 Million

27.08.2025 г., 22:56 ч. UTC

Печалби

South32 FY Total Capital Expenditure $1.35 Billion

27.08.2025 г., 22:56 ч. UTC

Печалби

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27.08.2025 г., 22:55 ч. UTC

Печалби

South32 Net Cash $123 Million at June 30

27.08.2025 г., 22:54 ч. UTC

Печалби

South32: Focused on Maintaining Strong Operating Momentum

27.08.2025 г., 22:53 ч. UTC

Печалби

South32: $144 Million Remains to be Returned to Shareholders Under Program

27.08.2025 г., 22:53 ч. UTC

Печалби

South32 Extends Capital Management Program for 12 Months

27.08.2025 г., 22:52 ч. UTC

Печалби

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27.08.2025 г., 22:51 ч. UTC

Печалби

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27.08.2025 г., 22:51 ч. UTC

Печалби

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27.08.2025 г., 22:50 ч. UTC

Печалби

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27.08.2025 г., 22:50 ч. UTC

Печалби

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27.08.2025 г., 22:45 ч. UTC

Печалби

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27.08.2025 г., 22:44 ч. UTC

Печалби

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27.08.2025 г., 22:44 ч. UTC

Печалби

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27.08.2025 г., 22:43 ч. UTC

Печалби

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27.08.2025 г., 22:43 ч. UTC

Печалби

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27.08.2025 г., 22:42 ч. UTC

Печалби

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27.08.2025 г., 22:42 ч. UTC

Печалби

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27.08.2025 г., 22:40 ч. UTC

Печалби

Sandfire Resources Net Debt $123 Million at June 30

27.08.2025 г., 22:40 ч. UTC

Печалби

Sandfire Resources FY Underlying Ebitda $527.7 Million

Сравнение с други в отрасъла

Ценова промяна

Ocular Therapeutix Inc Прогноза

Ценова цел

By TipRanks

36.61% нагоре

12-месечна прогноза

Среден 16.83 USD  36.61%

Висок 21 USD

Нисък 12.5 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Ocular Therapeutix Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

9

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

6.97 / 7.62Подкрепа & съпротива

Краткосрочен план

Bearish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

363 / 372 Класиране в Здравеопазване

Настроения в новините

Много силни мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.